Prof. Yaron Ilan is the Director of the Department of Medicine at the Hebrew University-Hadassah Medical Center. He graduated from the Hebrew University-Hadassah School of Medicine and completed his internship and residency at the Hadassah University Medical Center. His post-graduate training was acquired at the Liver Research Center of Yeshiva University’s Albert Einstein College of Medicine and Mount Sinai Medical Center in NYC. Between 2002 and 2009, he served as the Vice Dean of the Hebrew University-Hadassah Medical School. He was a visiting professor at the Harvard University Institute of Medicine. Prof. Yaron Ilan was the head of the Strategic Development Committee of Hadassah Medical Center. Between 2005 and 2008, he served as president of the Israel Liver Association. His main areas of research are bowel and liver immunology, the development of immunomodulatory drugs for fatty liver disease and diabetes, the development of therapies for inflammatory bowel diseases, and the development of drugs for primary liver cancer.
Short Biography
Prof. Yaron Ilan is the Director of the Department of Medicine at the Hebrew University-Hadassah Medical Center. He graduated from the Hebrew University-Hadassah School of Medicine and completed his internship and residency at the Hadassah University Medical Center. His post-graduate training was acquired at the Liver Research Center of Yeshiva University’s Albert Einstein College of Medicine and Mount Sinai Medical Center in NYC. Between 2002 and 2009, he served as the Vice Dean of the Hebrew University-Hadassah Medical School. He was a visiting professor at the Harvard University Institute of Medicine. Prof. Yaron Ilan was the head of the Strategic Development Committee of Hadassah Medical Center. Between 2005 and 2008, he served as president of the Israel Liver Association. His main areas of research are bowel and liver immunology, the development of immunomodulatory drugs for fatty liver disease and diabetes, the development of therapies for inflammatory bowel diseases, and the development of drugs for primary liver cancer.